Financials Evogene Ltd.

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 11:24:26 2026-10-29 EDT			5-day change	1st Jan Change
116.80 ^ILa	-0.93%		+3.00%	-61.14%

10-28	Evogene Ltd. Announces Acute Graft-Versus-Host Disease As The Target Indication For Its Internal AI-Driven Drug Discovery Program	CI
10-06	Evogene Enters into Cooperation Agreement with L.I.A. Pure Capital	CI

Projected Income Statement: Evogene Ltd.

Projected Income Statement - Annual - Evogene Ltd.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	0.93	1.675	5.64	8.511	3.853	1.436	2.6	4.95
Change	-	80.11%	236.72%	50.9%	-54.73%	-62.73%	81.06%	90.38%
EBITDA ¹	-	-	-22.04	-17.39	-12.89	-9.008	-8.9	-9.178
Change	-	-	-	21.13%	25.86%	30.12%	1.2%	-3.12%
EBIT ¹	-30.95	-26.94	-26.51	-22.21	-14.03	-10.14	-10.2	-10.63
Change	-	12.96%	1.61%	16.21%	36.81%	27.78%	-0.64%	-4.2%
Interest Paid	-1.414	-3.329	-	4.204	-	-	-	-
Earnings before Tax (EBT) ¹	-30.43	-29.75	-25.99	-18.04	-13.5	-12.17	-10.2	-10.63
Change	-	2.23%	12.66%	30.56%	25.2%	9.85%	16.18%	-4.2%
Net income ¹	-27.79	-26.64	-23.88	-16.48	-8.485	-12.17	-10.2	-10.63
Change	-	4.16%	10.36%	30.96%	48.53%	-43.42%	16.18%	-4.2%
Announcement Date	3/10/22	3/9/23	3/7/24	3/6/25	3/5/26	-	-	-

¹USD in Million

Estimates

Projected Income Statement - Quarterly - Evogene Ltd.

Fiscal Period: December	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	0.151	0.311	0.237	0.312	0.466	0.66	0.641	0.654	3.767	0.578	4.19	0.914	1.796	1.611	2.444	0.884	0.312	0.314	0.334	0.347	0.365	0.39
Change	-	105.96%	-23.79%	31.65%	49.36%	41.63%	-2.88%	2.03%	475.99%	-84.66%	624.91%	-78.19%	96.5%	-10.3%	51.71%	-63.83%	-64.71%	0.64%	6.37%	3.89%	5.19%	6.85%
EBITDA ¹	-	-	-	-	-	-	-5.737	-6.453	-2.977	-6.852	-3.415	-5.024	-6.352	-3.657	-3.231	-2.547	-2.416	-4.949	-2.957	-2.321	-1.993	-2.055
Change	-	-	-	-	-	-	-	-12.48%	53.87%	-130.16%	50.16%	-47.12%	-26.43%	42.43%	11.65%	21.17%	5.14%	-104.84%	40.25%	21.51%	14.13%	-3.11%
EBIT ¹	-8.556	-8.692	-8.055	-8.007	-7.097	-3.782	-6.796	-7.901	-4.183	-7.628	-4.086	-6.102	-7.455	-4.567	-4.126	-3.071	-2.724	-5.212	-3.15	-2.563	-2.343	-2.405
Change	-	-1.59%	7.33%	0.6%	11.37%	46.71%	-79.69%	-16.26%	47.06%	-82.36%	46.43%	-49.34%	-22.17%	38.74%	9.66%	25.57%	11.3%	-91.34%	39.56%	18.63%	8.58%	-2.65%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-8.335	-8.09	-9.104	-9.716	-7.158	-3.776	-7.026	-7.757	-3.863	-7.341	-3.845	-5.984	-8.218	0.002	-2.989	-3.528	-2.728	-5.338	-5.906	-1.591	-2.443	-2.555
Change	-	2.94%	-12.53%	-6.72%	26.33%	47.25%	-86.07%	-10.4%	50.2%	-90.03%	47.62%	-55.63%	-37.33%	100.02%	-149,550%	-18.03%	22.68%	-95.67%	-10.64%	73.06%	-53.55%	-4.58%
Net income ¹	-7.61	-7.371	-9.106	-8.821	-6.544	-2.998	-6.271	-7.023	-3.984	-6.601	-3.863	-5.419	-7.63	0.427	-2.587	-4.462	3.874	-5.309	-5.87	-1.768	-2.443	-2.555
Change	-	3.14%	-23.54%	3.13%	25.81%	54.19%	-109.17%	-11.99%	43.27%	-65.69%	41.48%	-40.28%	-40.8%	105.6%	-705.85%	-72.48%	186.82%	-237.04%	-10.57%	69.88%	-38.18%	-4.58%
Announcement Date	11/17/21	3/10/22	5/26/22	8/31/22	11/17/22	3/9/23	5/18/23	8/17/23	11/15/23	3/7/24	5/23/24	8/22/24	11/21/24	3/6/25	5/21/25	8/19/25	11/20/25	3/5/26	5/20/26	8/18/26	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Evogene Ltd.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	3/10/22	3/9/23	3/7/24	3/6/25	3/5/26	-	-	-

Estimates

Cash Flow Forecast: Evogene Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	0.682	0.847	1.171	0.785	0.626	0.135
Change	-	24.19%	38.25%	-32.96%	-20.25%	-78.43%
Free Cash Flow (FCF) ¹	-6.699	-17.97	-14.89	-12.6	-0.6336	-17.49
Change	-	-168.22%	17.15%	15.38%	94.97%	-2,661.04%
Announcement Date	4/2/21	3/31/22	3/30/23	3/28/24	3/27/25	3/26/26

¹USD in Million

Estimates

Forecast Financial Ratios: Evogene Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-	-	-390.87%	-204.29%	-334.54%	-627.3%	-342.31%	-185.41%
EBIT Margin (%)	-	-3,328.28%	-1,608.42%	-470%	-260.96%	-364.24%	-705.78%	-392.31%	-214.71%
EBT Margin (%)	-	-3,272.26%	-1,776.36%	-460.76%	-212.02%	-350.32%	-847.42%	-392.31%	-214.71%
Net margin (%)	-	-2,988.49%	-1,590.33%	-423.39%	-193.69%	-220.22%	-847.42%	-392.31%	-214.71%
FCF margin (%)	-	-	-	-	-	-	-	-	-
FCF / Net Income (%)	-	-	-	-	-	-	-	-	-
Profitability
ROA	-21.65%	-26.1%	-25.43%	-30.9%	-30.52%	-28.77%	-	-	-
ROE	-44.76%	-50.61%	-60.78%	-81.78%	-82.96%	-100.69%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	69.91%	-	-	-	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	12.99	7.852	7.024	4.106	2.349	1.486	-	-	-
Change	-	-39.54%	-10.54%	-41.54%	-42.8%	-36.73%	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	12.93	13.03	6.769	2.383	-0.2227	-0.009405	-	-	-
Change	-	0.76%	-48.06%	-64.8%	-109.35%	95.78%	-	-	-
EPS ¹	-8.301	-6.874	-6.464	-5.227	-2.894	-1.078	-	-	-
Change	-	17.19%	5.96%	19.14%	44.64%	62.76%	-	-	-
Nbr of stocks (in thousands)	3,557	4,116	4,122	5,055	6,515	8,716	-	-	-
Announcement Date	4/2/21	3/31/22	3/30/23	3/28/24	3/27/25	3/26/26	-	-	-